Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells 65,000 Shares of Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. The transaction was disclosed in a filing with the SEC, which is available at this link.

Thomas Gad also recently made the following trade(s):

• On Monday, September 16th, Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $12.97, for a total value of $389,100.00.

Y-mAbs Therapeutics Stock Up 10.0 %

NASDAQ YMAB traded up $1.30 on Tuesday, reaching $14.31. 316,236 shares of the stock traded hands, compared to its average volume of 352,311. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.69 and a 12 month high of $20.90. The firm’s fifty day simple moving average is $12.70 and its 200 day simple moving average is $13.52. The company has a market cap of $637.80 million, a price-to-earnings ratio of -29.20 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. During the same period in the prior year, the business earned ($0.14) EPS. As a group, equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in YMAB. Campbell & CO Investment Adviser LLC purchased a new position in Y-mAbs Therapeutics in the 4th quarter worth about $562,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares in the last quarter. Boston Partners acquired a new stake in shares of Y-mAbs Therapeutics during the first quarter valued at approximately $556,000. Finally, Rice Hall James & Associates LLC lifted its position in shares of Y-mAbs Therapeutics by 4.2% in the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after acquiring an additional 3,589 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. BMO Capital Markets decreased their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.